去纤维钠（去纤苷）适用于什么病症？

(Defibrinoside) is obtained from pig small intestinal mucosal genomic DNA through controlled depolymerization. Defibrinated sodium can be used clinically to treat multiple myeloma and hepatic veno-occlusive disease caused by chemotherapy and stem cell transplantation.

1. Defibrotide is used to prevent and treat hepatic veno-occlusive disease

Foreign studies have provided new evidence that DF protects vascular endothelium after stem cell transplantation. Chemotherapy and transplantation lead to the occurrence of vascular occlusion, and endothelial cell activation caused by occlusion is a common pathological injury. In the experimental design of this study, endothelial cells were incubated with defibrotide in advance, which can reduce the expression of ICAM-1 and block the activation of p38 and AKT, thereby preventing tissue damage caused by endothelial cell activation.

The enrolled cases all met the criteria for severe VOD. Some patients were prone to MOF and even had organ failure. They all showed significant curative effects after treatment with defibrotide. Some VOD patients have achieved complete remission, and their 100-day survival rate has also been significantly improved.

2. Fibroside is used in the treatment of multiple myeloma

Malignant plasma cells can cause the downregulation of tPA in vascular endothelial cells and the increase in PAI-1 secretion levels, especially when this effect is enhanced during thalidomide treatment. When plasma cells and endothelial cells are co-cultured, the addition of defibrinated sodium can upregulate tPA and downregulate PAI-1, which offsets the effect of thalidomide on endothelial cells and increases the specific cytotoxic effect of thalidomide on plasma cells.

A phase I/II clinical trial of defibrotide sodium to prevent deep venous thrombosis complications in multiple myeloma patients treated with thalidomide has been carried out. 24 patients with relapsed multiple myeloma were enrolled in the group and received anti-tumor drugs and combination drugs. The 1-year progression-free survival and overall survival were improved. Only one patient developed deep venous thrombosis, and the incidence of bleeding side effects was very low.

Recommended hot articles: /newsDetail/78559.html